Search Results for Fibrosis

S. A. Harrison et al. (University of Oxford, UK) report the development and validation of a blood-based diagnostic test to non-invasively rule in and rule out at-risk NASH. In their prospective derivation and global validation study, derivation was done in the discovery cohort, which comprised 239 prospectively recruited patients with...

The association of free testosterone with NASH was determined in pre-menopausal women with biopsy-confirmed NAFLD. Interaction testing was performed for age and free testosterone given decline in testosterone with age, and association of aging with...

Liver stiffness, as assessed by vibration-controlled transient elastography (VCTE), correlates with hepatic fibrosis, an important predictor of liver-related and all-cause mortality. Although liver fat is associated with cardiovascular risk factors, the association between hepatic fibrosis and cardiovascular risk factors is less clear...

Non-invasive tests of NAFLD can be classified by the target disease state or the type of test. Disease states of interest include the detection of hepatic steatosis (for the diagnosis of NAFLD or using steatosis improvement as treatment outcomes in early phase studies)...

Although recent evidence suggests the involvement of iron accumulation in the pathogenesis of NASH, the underlying mechanisms remain poorly understood. Previously, Y. Kanamori et al. (Nagoya, Japan) reported a unique histological structure termed ‘‘crown-like structure (CLS),’’ where liver-resident macrophages (Kupffer cells) surround...

SA Alqahtani et al. remind us of the burden of non-alcoholic fatty liver disease (NAFLD). In the USA, it is the most common cause of chronic liver disease and the prevalence is estimated to be about 25% and will increase in future years. For the management of patients with NAFLD, the determination of the fibrosis is essential. Liver biopsy is the gold standard...